Cascade Investment Advisors Inc. Lowers Position in Eli Lilly and Company (NYSE:LLY)

Cascade Investment Advisors Inc. lessened its position in Eli Lilly and Company (NYSE:LLYFree Report) by 7.0% in the first quarter, HoldingsChannel reports. The firm owned 360 shares of the company’s stock after selling 27 shares during the quarter. Cascade Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $280,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Lipe & Dalton purchased a new position in Eli Lilly and Company during the fourth quarter valued at $26,000. Tidemark LLC purchased a new position in Eli Lilly and Company during the fourth quarter valued at $29,000. Core Wealth Advisors Inc. raised its stake in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the last quarter. Optiver Holding B.V. purchased a new position in Eli Lilly and Company during the third quarter valued at $36,000. Finally, Frank Rimerman Advisors LLC purchased a new position in Eli Lilly and Company during the fourth quarter valued at $37,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Bank of America lifted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. BMO Capital Markets lifted their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Finally, Argus lifted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $769.53.

Check Out Our Latest Analysis on LLY

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $5.21 during trading hours on Thursday, hitting $808.12. The company’s stock had a trading volume of 3,024,199 shares, compared to its average volume of 3,006,071. The business has a 50 day moving average price of $764.43 and a two-hundred day moving average price of $690.85. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $820.60. The company has a market cap of $768.05 billion, a PE ratio of 119.02, a PEG ratio of 1.75 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the business earned $1.62 earnings per share. The business’s revenue was up 26.0% on a year-over-year basis. Analysts expect that Eli Lilly and Company will post 13.78 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.64%. Eli Lilly and Company’s payout ratio is 76.58%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.